This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The field of genomics has witnessed a revolutionary transformation, leading to a better understanding of health and disease, as well the emergence of personalized medicine to improve therapeutic outcomes. Book your tailored demo
How to Create Optimal Territories with Key Opinion Leaders and Patient Demographics As the role of the Medical Science Liaison (MSL) has evolved from academic rigor to understanding disease trends, a key component of MSL territory planning is collaboration with Key Opinion Leaders (KOLs). But what happens when knowledge gaps exist?
Ariel Katz , CEO & Co-Founder AI will be used to combat rare diseases. In 2025, we will see AI leveraged for faster, more accurate diagnoses in rare disease cases, reducing the rate of more than a quarter of rare disease patients who spend 7+ years until they receive a correct diagnosis (up from 15% from 30 years ago).
Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. Find out more by requesting a demo today. I am thankful that the FDA is taking this step in the right direction for all of us.”H1
To learn more about how H1 can help diversify your HCP engagement strategy, request a demo. When planning a drug development program, it’s essential to consider the diversity of patient populations that will be recruited into clinical trials.
Medical Affairs Strategies that Demonstrate and Improve Impact Medical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Request a demo today to learn more. Their knowledge is crucial as medications become more specialized and complex.
This is especially true for rare disease populations, where understanding the nuances between different patient cohorts is key to achieving positive outcomes. To learn more about how to leverage performance data in your trial planning, request a demo of H1’s Clinical Trial Intelligence solution – Trial Landscape. The Michael J.
ramps up for release of the latest COVID-19 vaccine booster, the Centers for Disease Control and Prevention (CDC) recommends that all Americans aged 6 months and older receive the updated COVID booster amid rising cases and hospitalizations across the country. Request a demo of Trial Landscape.
Contact our team today for a demo. link] Center for Disease Control and Prevention (CDC). Organizations should act now to strategically incorporate technology that can streamline the balancing act of patient care and staffing. Ready to Enable Your Workforce for The Current and Future Demand? References: AARP. link] Gartner.
Personalizing Treatments ML algorithms can analyze extensive medical records to detect patterns and characteristics, such as genetic markers or disease progression trends, to identify specific patient subgroups that may respond differently to treatments. Connect with a team member to learn more or request a demo of our technology!
This gene is shared by monkeys and humans and, when it’s mutated in juuuust the right way, can lower LDL and reduce heart disease risk. Event Spira, a company that uses engineered algae to manufacture pigments, is having a free demo in San Francisco on Thursday, May 25th. Again, this is a big deal. Open to all. Come say hi!
A live demo is available online, but “it chews through OpenAI credits,” Patel says. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources. “Every query is like $2.” A Mycoplasma cell.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources. “Every query is like $2.” A Mycoplasma cell.
This gene is shared by monkeys and humans and, when it’s mutated in juuuust the right way, can lower LDL and reduce heart disease risk. Event Spira, a company that uses engineered algae to manufacture pigments, is having a free demo in San Francisco on Thursday, May 25th. Again, this is a big deal. Open to all. Come say hi!
Combatting malaria, dengue, and other diseases will be the great medical achievement of our generation. The demos are this Sunday, June 4th! R21, developed at the University of Oxford, was up to 80% effective in a small clinical trial of 450 children in Burkina Faso. Mosquitoes kill more humans, by far, than any other animal.
Combatting malaria, dengue, and other diseases will be the great medical achievement of our generation. The demos are this Sunday, June 4th! R21, developed at the University of Oxford, was up to 80% effective in a small clinical trial of 450 children in Burkina Faso. Mosquitoes kill more humans, by far, than any other animal.
For delegated acts, the co-legislators usually have two months to object to the proposals but cannot amend them. For implementing acts, the Commission is required to consult with a committee before adoption.
A concerned employee at a laboratory supply company had called the Centers for Disease Control, or CDC, after fielding repeated calls from Harris asking when his samples of plague would arrive in the mail. Entering the DNA sequence into the SecureDNA demo also outputs variola virus, much like BLAST, but it happens in a fraction of the time.
Without access to all the relevant data, researchers are unable to fully understand the complexities of diseases and develop effective treatments. Case Study: Equitable Clinical Trial Access for Women, Minorities Among Cardiovascular Disease in the U.S. To learn more, request a demo.
Going from a demo in a Jupyter notebook (used to write Python code) to getting something that can run at scale is a lot of work. Biosecurity is always a challenging question because our goal is to manipulate human biology to cure disease. White: I thought that most things were going to be hard, actually. We think about it a lot.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content